Upload
letuong
View
217
Download
4
Embed Size (px)
Citation preview
SANGEETA MARUTI BHORADE, M.D., FCCP
The pulmonary council of the ISHLT has advanced the field of lung transplantation on an
international level. As Vice Chair of the pulmonary council, I hope to continue to further
the field in new and innovative ways. I have been involved with ISHLT for
approximately 14 years. Over this time, I have gained an appreciation for the mission of
the Pulmonary Council. I am currently the Medical Director of the Lung Transplant
Program at the University of Chicago. I have been involved with clinical and
translational research in lung transplantation including the evaluation of
immunosuppression during this time. In addition to identifying clinical projects of
interest, I believe that developing collaborations both within our society as well as with
other societies will greatly enhance our productivity. I am committed to devote my time
and expertise to assist this organization to further the field of lung transplantation through
education, research and collaborations. Thank you.
CURRICULUM VITAE
SANGEETA MARUTI BHORADE, M.D., FCCP
PERSONAL DATA
Business Address: University of Chicago Medical Center and Pulmonary Clinic
5841 South Maryland Ave MC 0999
Chicago, IL 60611
Home Address: 440 North McClurg Court #422
Chicago, Il 60611
312-645-0021
Place of Birth: Chicago, IL
EDUCATION
1984-1988 University of Chicago B.A., Biology/Behavioral Science
1988-1992 University of Chicago Pritzker School of Medicine, M.D.
POSTDOCTORAL TRAINING
1992-1993 Intern, Department of Medicine, University of Chicago
1993-1995 Resident, Department of Medicine, University of Chicago
1995-1998 Fellow, Section of Pulmonary/Critical Care, University of Chicago
ACADEMIC APPOINTMENTS
1998-1999 Instructor, Department of Medicine, Loyola University Medical Center
1999-2005 Assistant professor, Department of Medicine, Loyola University Medical
1999-2005 Associate Medical Director, Loyola Lung Transplant Program 2005-present Associate Professor of Medicine, Dept of Medicine, University of Chicago
2005-present Medical Director, Lung Transplant Program, University of Chicago
BOARD CERTIFICATION AND LICENSURE
2000 Board Certified, Critical Care Medicine
2010 Board Recertification, Critical Care medicine
1997 Board Certified, Pulmonary Medicine
2008 Board Recertification, Pulmonary medicine
1995 Board Certified, Internal Medicine
2006 Board Recertification, Internal Medicine
1994 Diplomate of the National Board of Medical Examiners
Illinois License # 036-090203
HONORS AND AWARDS
2001 Boehringer-Ingelheim Leadership Award in Pulmonary Medicine
1999 Leadership development Award-ACCP
1989 University of Chicago Summer Research Neurobiology Award
1988 Graduation with Honors in Behavioral Science
1988 Howell Murray Award (Awarded to the top 10 Seniors excelling in
extracurricular activities in the College)
Morton-Murphy Award (Extracurricular Achievement in the College)
COMMITTEE MEMBERSHIP
2010-2012 ATS Ethics and Conflict of Interest Committee 2010-2011 UNOS/OPTN Thoracic Committee 2006-2011 ACCP Transplantation Network Steering Committee 2007-2009 UNET Appeal board for lung transplantation
2007- Fellowship Selection Committee Member, Section of Pulmonary/ Critical
Care, University of Chicago Medical Center
2006-2009 Gift of Hope Medical Advisory Committee Member
2006-2008 Thoracic Transplantation Committee, American Society of
Transplantation
2005-2006 Secretary/ Treasurer; Chicago Thoracic Society
2004-2005 Member, Clinical Research Advisory Committee, LUMC
2003- 2005 Member, Institutional Review Board, Loyola University Medical Center
2003-2004 Secretary/ Treasurer; Chicago Thoracic Society
2002-2005 Residency Review Committee, Loyola University Medical Center
2001-2005 Chicago Thoracic Society Programming Committee
2000-2005 Infection control Committee, Loyola University Medical Center
1999-2005 Fellowship Training Committee- Loyola University Medical Center
1999-2005 Intern Recruitment Committee- Loyola University Medical Center
1999-2005 Internal medicine interest group mentor- Loyola University Medical
Center
MEMBERSHIPS IN PROFESSIONAL SOCIETIES
1999-present American Society of Transplant Physicians
1999- present International Society of Heart and Lung Transplantation
1997- present American College of Chest Physicians (FCCP, 2000)
1995- present American Thoracic Society
1994- present American College of Physicians
TEACHING EXPERIENCE
2006- present Lecturer- Lung Transplantation. Pulmonary Fellow Conference U of Chicago.
2005- present Discussant, Internal Medicine Morning Report, U of Chicago Medical Center
2005-present Discussant, Pulmonary/ Critical Care Morning Report, U of Chicago
2005- present Discussant, Morbidity and Mortality, University of Chicago Medical Center
2005- present Lecturer, Dept of Medicine Resident Lecture Series- Lung Transplantation
2007 University of Chicago Undergraduate Course. Lung Transplantation
2007 Loyola University Medical Center. Methods of Clinical Research.
2007-present U of Chicago Nursing Education. Selection criteria for lungtransplantation.
2004 LUMC fellows grand rounds: Management of malignant pleural effusions.
2004-2005 Preceptor for 1st year medical students- Introduction to Epidemiology
2002- 2005 Preceptor for 2nd
year medical students- Physical Examination
2001 LUMC fellows grand rounds: Idiopathic pulmonary fibrosis and other
interstitial lung diseases
2003- 2005 Case Discussion-DVT/PE- 2nd
year medical students
2001- 2005 Internal medicine resident board review-Interstitial lung disease
2000-2005 Mechanisms of Human Disease Class- 2nd
year medical students
1999-2005 Introductory lecture series for pulmonary fellows-LUMC Interstitial lung disease
1998-2005 Lecture series for students/ residents rotating on the Pulmonary service-
LUMC Pulmonary hypertension, Interstitial lung disease
2003 Pulmonary Care: Hospital to Home Sponsored by Loyola University
Medical Center Department of Nursing Education and Support Services.
Idiopathic Pulmonary Fibrosis
2001 Pulmonary Care: Hospital to Home Sponsored by Loyola University
Medical Center Department of lung transplant medicine and Nursing
Education and Support Services. Asthma., Lung cancer
2001 End stage lung disease symposium; Loyola University Medical
Center(coursedirector):
2002 End stage lung disease symposium. Loyola University Medical Center (co-course
director):
1993-1995 Teaching Assistant, Physical Diagnosis
1992-1994 Medical Resident preceptor for medical students
MENTORSHIP
Scholarship and Discovery Program for Medical Students
PJ McShane (University of Chicago)
2007-2010 MD Immunosuppressive regimens in lung transplantation
Instructor University of Chicago
Jaime Villanueva (Loyola University Medical Center)
1998-2001 MD Immunosuppressive regimens after lung transplantation
Private Practice of Pulmonary and Critical Care Medicine, Chicago Metropolitan Area
Ashby Jordan (Loyola
2000-2003 MD Immunosuppressive regimens after
Private Practice of Pulmonary and
University Medical Center)
lung transplantation
Critical Care Medicine, Chicago Metropolitan Area
Andrew Yu (Loyola University Medical Center)
2001-2004 MD Assessment of pro-inflammatory cytokines after lung transplantation
Private Practice of Pulmonary and Critical Care Medicine, Chicago Metropolitan Area
Brandon Lu (Loyola University Medical Center)
2002-2005 MD Differential gene expression profiling in lung transplant recipients
Instructor, Northwestern University Medical Center
REVIEWER
1. American Journal of Respiratory and Critical Care Medicine
2. AJP: Lung Cellular and Molecular Physiology
3. Chest
4. Journal of Heart and Lung Transplantation
5. Transplantation
6. American Journal of Transplantation
7. Respiratory Medicine
8. Clinical Transplantation
9. British Medical Journal
10. Transplant Infectious Disease
11. International journal of respiratory diseases
12. Annals of Transplantation
13. Abstract reviewer for the International Society of Heart and Lung Transplantation
14. Abstract reviewer for American College of Chest Physicians
15. Grant reviewer for American College of Chest Physicians
Ad hoc grant reviewer for FDA Office of Orphan Product Development May 2011
Editorial positions 1. ISRN pulmonology
PUBLICATIONS
Peer reviewed Clinical Investigations:
1. Floreth T, Stern E, Tu Y, Stern R, Garrity ER Jr, Bhorade SM, White SR.
Differentiated transplant derived airway epithelial cell cytokines secretion is not
regulated by cyclosporine. Respir Res 2011; 12: 44.
2. Sims MW, Beers MF, Ahya VN, Kawut SM, Sims KD, Lederer DJ, Palmer SM, Wille
K, Lama V, Shah PD, Orens JB, Bhorade S, Crespo M, Weinacker A, Demissie E,
Bellamy S, Christie JD, Ware LB; for the Lung Transplant Outcomes Group. Effect
of single versus bilateral lung transplantation on plasma surfactant protein D levels in
idiopathic pulmonary fibrosis. Chest 2011 (epub)
3. Vigneswaran WT, Helenowski M, Bhorade SM, Lamounier F, Alex C, Garrity ER Jr.
Early readmission is a predictor of overall survival following isolated lung
transplantation . Int Surg 2010; 95: 299-304.
4. Diamond JM, Kawut SM, Lederer DJ, Ahya VN, Kohl B, Sonett J, Palmer SM, Crespo
M, Wille KM, Lama V, Shah PD, Orens J, Bhorade S, Weinacker A, Demissie1 E,
Bellamy S, Christie JD, and Ware LB for the Lung Transplant Outcomes Group.
Elevated Plasma Clara Cell Secretory Protein Concentration is Associated with High
Grade Primary Graft Dysfunction. Am J Transplant 2011; 11: 561-567.
5. Ahya VN, McShane PJ, Baz MA, Valentine VG, Arcasoy SM, Love RB, Seethamraju
H, Garrity E, Alex CG, Bag R, Deoliveira NC, Vigneswaran WT, Charbeneau J,
Krishnan JA, Durazo-Arvizu R, Norwick L, Bhorade S. Increased risk of venous
thromboembolism with a sirolimus based immunosuppression regimen in lung
transplantation. J Heart Lung Transplant 2011; 30: 175-181.
6. Bhorade S, Ahya VN, Baz MA, et al. Comparison of sirolimus to azathioprine in a
tacrolimus based immunosuppressive regimen in lung transplantation. Am J Respir
Crit Care Med 2011; 183: 379-387.
7. Bhorade SM, Chen H, Molinero L, et al. Decreased percentage of CD4+FoxP3+ cells
in bronchoalveolar lavage from lung transplant recipients correlates with development
of bronchiolitis obliterans syndrome. Transplantation 2010;15: 540-546.
8. Sandbo N, Kregel S, Taurin S, Bhorade S, Dulin NO. Critical role of serum response
factor in pulmonary myofibroblast differentiation induced by TGF beta. Am J Respir
Cell Mol Biol 2009; 41: 332-338.
9. Bhorade SM, et al. Cylex immunoassay levels are lower in lung transplant recipients
with infection. The Journal of Heart and Lung Transplantation 2008; 27: 990-994.
10. Vigneswaran WT, Bhorade S, Wolfe M, Pelletiere K, Garrity ER. Clinical pathway
after lung transplantation shortens hospital length of stay without affecting outcome.
Int Surg 2007; 92: 93-98.
11. Bhorade SM, et al.Elevation of IL15 protein expression in bronchoalveolar fluid in
acute lung allograft rejection. Chest 2007: 131; 533-538.
12. Lu BS, Yu AD, Zhu X, Garrity ER, Vigneswaran WT, Bhorade SM. Sequential gene
expression profiling in lung transplant recipients with chronic rejection. Chest.
2006;130:847-854
13. Villanueva J, Boukhamseen A, Bhorade, SM. Successful Use in Lung
Transplantation of an Immunosuppressive Regimen Aimed at Reducing Target Blood
Levels of Tacrolimus and Sirolimus Journal of Heart & Lung Transplantation.
24(4):421-5, 2005 Apr.
14. Lurain NS, Fox AM, Lichy HS, Bhorade SM, Ware CF, Huang DD, Kwan SP,
Garrity ER, Chou S. Analysis from the human cytomegalovirus genomic region from
UL146 through UL147A reveals sequence hypervariability, genotypic stability, and
overlapping transcripts. Virol J. 2006 Jan 12;3(1):4
15. Bhorade SM, Jordan AM, Villanueva J, et al. A comparison of three tacrolimus
based immunosuppressive regimens in lung transplantation. American Journal of
Transplantation 2003; 3: 1570-1575.
16. Lurain N, Bhorade S. et al. Antiviral drug resistant cytomegalovirus in solid organ
transplant recipients. Journal of Infectious Disease 2002; 186: 760-768.
17. Vigneswaran WT, Sakiyalk P, Bhorade SM. Airway complications following
isolated lung transplantation. Transplantation Reviews 2002; 16 (2):87-94.
18. Bhorade SM, Lurain NS, Jordan A, et al. Emergence of ganciclovir resistant
cytomegalovirus in lung transplant recipients Journal of Heart and Lung
Transplantation 2002; 21 (12): 1274-1283.
19. Lanuza DM. Lefaiver CA. McCabe MA. Farcas GA. Bhorade SM. Garrity ER.
Functional status and medical complications during the first year post lung
transplantation (LTX). Journal of Heart & Lung Transplantation. 20(2):204, 2001
20. Bhorade SM, Sandesara C, Garrity E, Norwick L, Vigneswaran WT, Alkan S, Husain
A, McCabe MA, Yeldandi V. Quantification of cytomegalovirus viral load by the
hybrid capture assay allows for early detection of CMV disease in lung transplant
recipients. Journal of Heart & Lung Transplantation. 20(9):928-34, 2001 Sep.
21. Villanueva J, Bhorade SM, Robinson J, Husain AN, Garrity ER. Extracorporeal
Photopheresis for the Treatment of Lung Allograft Rejection Annals of Transplantation. 5(3):44-7, 2000.
22. Garrity ER, Villanueva J, Bhorade SM, et al. Reduction of acute lung allograft
rejection by daclizumab an interleukin-2 receptor antibody. Transplantation 2001; 71:
773-777.
23. Bhorade SM, Vigneswaran W , McCabe MA, Garrity ER. Liberalization of donor
criteria may expand the donor pool without adverse consequence in lung
transplantation. Journal of Heart and Lung Transplantation 19 (12): 1199-1204, 2000.
24. Christenson J, Lavoie A, O’Connor M, Bhorade S, Pohlman A, Hall JB. The
incidence and pathogenesis of cardiopulmonary deterioration following the abrupt
withdrawal of inhaled nitric oxide. American Journal of Respiratory and Critical Care
Medicine 161 (5):1443-1449,2000
25. Bhorade S, Christenson J, O’ Connor M, Lavoie A, Pohlman A, Hall JB. The
response to inhaled nitric oxide in patients with acute right heart syndromes. American
Journal of Respiratory and Critical Care Medicine 159 (2): 571-602, 1999.
26. Bhorade S, Christenson J, Pohlman A, Hall JB. The incidence of and clinical
variables associated with vancomycin resistant enterococcal colonization in
mechanically ventilated patients. Chest 115(4): 1085-1092, 1999.
Invited Review manuscripts:
1. Floreth T, Bhorade SM, Ahya VN. Conventional and Novel Approaches to
Immunosuppression. Clin Chest Med. 2011 Jun;32(2):265-77
2. Ramaprasad C, Zamora MR, Hopkins P, Bhorade SM. Influenza and other seasonal
respiratory viruses in cardiothoracic transplantation. Journal of Heart Lung
Transplantation (in press)
3. McShane PJ, Bhorade SM. Immunosuppression following lung transplantation. In:
UpToDate, Basow (ed), UpToDate, Waltham, MA, 2009
4. Floreth T, Bhorade SM. Current trends in immunosuppression. Seminars in
Respiratory and Critical Care Medicine 2010; 31:172-178.
5. Brush DR, Bhorade SM. Interstital lung disease and lung transplantation. Minerva
Pneumol 2008; 47: 53-62.
6. Stern E, Bhorade SM. Lung transplantation: the new lung-allocation system.
Expert review of respiratory medicine 2008; 2: 473-478.
7. Bhorade SM. Cyclosporine chapter in Administration and Monitoring of
Immunosuppressive Drugs in Lung Disease and Lung Transplant Patients: ACCP
Evidence-Based Clinical Practice Guidelines 2008- (in press)
8. Stern E, Bhorade SM. Immunosuppression after lung transplantation. Proceedings
of the American Thoracic Society 2009 Jan 15;6(1):47-53.
9. Meyer N, Bhorade SM. Evolving immunosuppression for lung transplantation.
Seminars in Respiratory and Critical Care Medicine 2006; 27: 470-479.
10. Orens JB, Shearon TH, Greudenberger RS, Conte JV, Bhorade SM, Ardehali A.
Thoracic organ transplantation in the United States 1995-2004. Am J Transplant
2006;6: 1188-1197
11. Bhorade SM and Lu B. Lung transplantation for interstitial lung disease. Clinics in
Chest Medicine 2004; 25; 773-782.
12. Bhorade SM, Villanueva J, Jordan A, Garrity ER. Immunosuppressive Regimens in
Lung Transplantation. Drugs of Today 2004; 40: 1003-1012.
13. Bhorade SM et al. Community respiratory viral infections in the lung transplant
recipient. The American Journal of Pulmonary Review 2003; 1:14-15.
14. Jordan AM, Bhorade SM. Lung Transplantation for Cystic Fibrosis. Current
Opinion in Organ Transplantation.2002; 7:254-259.
Abstracts:
1. H.Y. Robbins, S.M. Arcasoy, S. Bhorade, M.M. Crespo, S.M. Kawut, V.N. Lama, J.B.
Orens, S.M. Palmer, P.D. Shah, R. Shah, J.R. Sonett, L.B. Ware, A. Weinacker, K.M.
Wille, J.D. Christie, D.J. Lederer. Temporal Trends in the Prevalence of Primary Graft
Dysfunction after Lung Transplantation in the Lung Transplant Outcomes Group (LTOG)
Cohort. J Heart Lung Transplant 2011 (oral presentation)
2. J.M. Diamond, R. Feng, N. Meyer, D. Lederer, J. Lee, S. Kawut, V. Ahya, E. Cantu, S.
Palmer, A. Weinacker, S. Bhorade, V. Lama, J. Orens, J. Sonett, K. Wille, M. Crespo, D.
Weill, B. Kohl, C. Deutschman, S. Arcasoy, A. Shah, P.D. Shah, E.J. Demissie, J.
Reynolds, J. Belperio, D. Wilkes, L. Ware, J.D. Christie PTX3 Polymorphisms Are
Associated with Primary Graft Dysfunction after Lung Transplantation. J Heart Lung
Transplant 2011 (oral presentation)
3. D.J. Lederer, S.M. Kawut, N. Wickersham, C. Winterbottom, J. Diamond, S. Bhorade,
S. Palmer, J. Lee, K.M. Wille, A. Weinacker, V. Lama, M. Crespo, J. Orens, S.M.
Arcasoy, L. Ware, J.D. Christie. Higher Plasma Leptin Levels Are Associated with
Primary Graft Dysfunction after Lung Transplantation: The LTOG Obesity Study. J
Heart Lung Transplant 2011 (oral presentation)
4. J.M. Diamond, D. Lederer, S.M. Kawut, J. Lee, E. Cantu, V. Ahya, S. Palmer, A.
Weinacker, S. Bhorade, V. Lama, J.B. Orens, J. Sonett, K. Wille, M. Crespo, D. Weill,
B. Kohl, C. Deutschman, S. Arcasoy, A. Shah, P.D. Shah, E.J. Demissie, J.M. Reynolds,
J. Belperio, D. Wilkes, L. Ware, J.D. Christie. Elevated PTX3 Concentration Is
Associated with Primary Graft Dysfunction. J Heart Lung Transplant 2011 (oral
presentation)
5. M.J. Russo, K.N. Hong, A. Iribarne, J. Costa, E. Garrity, S. Bhorade, W. Vigneswaran,
J.R. Sonett Age Greater Than 70 Is Associated with Diminished Post-Lung Transplant
Survival. J Heart Lung Transplant 2011 (oral presentation)
6. T. Floreth, R. Stern, B. Laxman, E. Garrity, S. Bhorade, S.R. White. Human Leukocyte
Antigen-G Concentrations in Plasma and BALF Are Inversely Correlated to High Grade
Acute Rejection in Lung Transplantation. J Heart Lung Transplant 2011 (oral
presentation)
7. Ghassemieh, Charbeneau, Ahya, Baz, Valentine, Arcasoy, Love, Seethamraju, Alex,
Bag,. DeOliveira, Husain, Vigneswaran, Krishnan, Durazo-Arvizu, Norwick, Garrity, S.
Bhorade. Decreased CMV Infection with Sirolimus Compared to Azathioprine after
Lung Transplantation. J Heart Lung Transplant 2011 (poster presentation)
8. Zhang W, Zhou T, Machado R, Bhorade S, and Garcia JG. MicroRNAs Are Implicated
In Gene Expression Dysregulation In Lung Transplant Patients. Am. J. Respir. Crit. Care
Med., May 2011; 183: A4019. (oral presentation)
9. Stern E, Tu Y, Stern R, Marroquin B, Bhorade S, and White SR. Cyclosporine Does Not
Affect Cytokine Secretion Of Differentiated Allograft Epithelial Cells Am. J. Respir.
Crit. Care Med., May 2010;181: A6434.
10. Shah, Diamond, Ahya, Arcasoy, Belperio, Bhorade, Cantu, Crespo, Deutschman,
Demissie, Kawut, Kohl, Lama, Lederer, Lee, Orens, Palmer, Reynolds, Shah, Pali Shah,
Sonett, Wille, Weinacker, Wilkes, Ware, Weill, and Christie. Elevated Monocyte
Chemotactic Protein-1 (MCP-1) Is Associated With Primary Graft Dysfunction
Following Lung Transplantation. Am. J. Respir. Crit. Care Med., May 2011; 183: A4023.
(oral presentation)
11. Joshua M. Diamond, Rui Feng, Nuala J. Meyer, Steven M. Kawut, James C. Lee, Vivek
Ahya, Edward Cantu, Lorraine Ware, Scott M. Palmer, Sangeeta Bhorade, Vibha Lama,
Ann Weinacker, Jonathan B. Orens, Joshua Sonett, Keith M. Wille, Maria Crespo, David
Weill, Benjamin Kohl, Clifford Deutschman, Selim M. Arcasoy, Ashish Shah, Pali Shah,
E.J. Demissie, John Reynolds, John A. Belperio, David Lederer, and Jason D. Christie.
Genetic Variation In Prostaglandin E2 Family Members Is Associated With The
Development Of Primary Graft Dysfunction After Lung Transplantation. Am. J. Respir.
Crit. Care Med., May 2011; 183: A4014. (oral presentation)
12. Bhorade S, Johnson BA, Johnson ,e t al. Inhaled cyclosporine provides high lung
concentrations, low systemic exposure and is well tolerated: An interim report on the
Cyclist Clinical Trial. 9th
International congress on lung transplant Paris France
September 2010(oral presentation)
13. I.O. Gordon, S. Bhorade, W.T. Vigneswaran, P.J. McShane, E.R. Garrity, A.N. Husain :
SaLUTaRy: Survey of Lung Transplant Rejection J Heart Lung Transplant 2010 (oral
presentation)
14. Bhorade SM et al Bronchoalveolar lavage fluid Fox P3+ T cells are decreased in lung
transplant recipients with bronchiolitis obliterans syndrome. J Heart Lung Transplant
2009 (oral presentation)
15. McShane PJ, Bhorade SM et al Sirolimus is a ssociated with an increased risk of
venous thromboembolism in lung transplantation. J Heart Lung Transplant 2009(oral
presentation)
16. Bhorade SM et al Long term follow-up in the AIRSAC trial, a multicenter randomized
clinical trial in lung transplant recipients. J Heart Lung Transplant 2009(oral
presentation)
17. Bhorade SM et al Interobserver variability of acute cellular lung rejection: A review of
310 surveillance biopsies from the AIRSAC trial American Thoracic Society
2009(poster discussion)
18. Bhorade, SM, et al. Comparison of Infection Rates between Sirolimus and Azathioprine
in a Tacrolimus Based Immunosuppressive Regimen after Lung Transplantation Am J Respir Crit Care Med 2008
19. Bhorade, SM, et al. Comparison of a tacrolimus/sirolimus/prednisone regimen versus
tacrolimus/ azathioprine/prednisone immunosuppressive regimen in lung transplantation
Journal of Heart and Lung Transplantation 2008(oral presentation)
20. Bhorade SM et al. Acute rejection and infection episodes modify the chemokine milieu
in human lung allografts. American Immunology Conference 2007(oral presentation)
21. S.M. Bhorade, V. Ahya, R. Kotloff, et al. Incidence of Renal Failure in Lung Transplant
Recipients Receiving Tacrolimus and Sirolimus Immunosuppressive Regimen. Journal
of Heart and Lung Transplantation 2006
22. Lu B, Garrity ER, Ahya V, Kotloff R, Baz M, Valentine V, Arcasoy S, Love R, Bhorade
S. Utility of surveillance bronchoscopy after lung transplantation. Am J Respir Crit Care Med 2005: A892. (oral presentation)
23. Janata RJ, Bhorade SM, Villanueva J. Outcome of lung transplant recipients following
admission to a long term acute care facility. Am J Respir Crit Care Med 2005: A892. 24. Janata KR, Lu B, Sinecore J, Garrity ER, Bhorade S. Measurement of
immunosuppression by the cylex immunoassay in lung transplantation patients. Am J Respir Crit Care Med 2005: A420.
25. Lu BS, Garrity ER, Bhorade SM. Prevalence and outcome of post- transplant
lymphoproliferative disorder in lung transplantation. Am J Respir Crit Care Med 2005: A420.
26. Janata RJ, Bhorade SM, Villanueva J. Outcome of lung transplant recipients following
admission to a long term acute care facility. Am J Respir Crit Care Med 2005: A418. 27. Janata RJ, Riker D, Bhorade SM, et al. Incidence of sleep disturbances in medical
students. Am J Respir Crit Care Med 2005: A758. 28. Bhorade SM, Ahya V, et al. Six month results of sirolimus versus azathioprine in a
tacrolimus based immunosuppressive regimen in lung transplantation. J Heart Lung
Transplantation 2005: 24 S26 (oral presentation)
29. Pelletiere K, Vigneswaran WT, Bhorade S., et al. Critical pathway and strategies to
improve lung transplant outcome. Chest 2004; 126: 844s.
30. Janata KR, Lu B, Bhorade SM, et al. Reduction of Fas Ligand levels in bronchoalveolar
lavage fluid in lung transplant recipients. J of Heart Lung Transplantation 2005; 24: S54.
31. Shah SH, Vigneswaran WT, Bhorade S., et al. Reducing corticosteroid administration
decreases the incidence of opportunistic infection following lung transplantation without
increasing early rejection. Chest 2004; 126: 712s.
32. Lu BS, Yu AD, Cao GC, Garrity ER, Vigneswaran WT, Bhorade SM. Sequential gene
expression profiling of lung transplantion recipients with acute rejection. Am J Respir Crit
Care Med 2004: A505.
33. Lu BS, Yu AD, Cao GC, Garrity ER, Vigneswaran WT, Bhorade SM. Temporal gene
expression profiling of lung transplantion recipients with acute rejection. Am J Respir Crit
Care Med 2004: A271.
34. Yu AD, Bhorade SM, Lu BS, DiPietro L, Garrity ER. Evaluation of fibroblast growth
factor in lung transplant recipients with sarcoidosis. Am J Respir Crit Care Med 2004:
A102.
35. DeFay R, Villanueva J, Kramer H, Garrity E, Bhorade SM. Outcomes of lung transplant
recipients in the medical intensive care unit. Am J Respir Crit Care Med 2004: A101
36. Yu AD, BS Lu, Vigneswaran, Garrity ER, Bhorade SM. Elevated IL15 in acute lung
allograft rejection. Journal of Heart and Lung Transplantation 2004; 23: s165. (oral
presentation)
37. Lu BS, Yu AD, Cao GG, Garrity ER, Vigneswaran WT, Bhorade SM. Differential gene
expression profiling in lung transplant recipients with chronic rejection. Journal of Heart
and Lung Transplantation 2004; 23: S131. (oral presentation)
38. Bhorade SM, et al. Comparison of sirolimus versus azathioprine in a tacrolimus based
immunosuppressive regimen in lung transplantation. Journal of Heart and Lung
Transplantation 2004; 23: S113.
39. Jordan A, Bhorade SM, et al. Sirolimus for the treatment of Bronchiolitis obliterans
sydrome. Am J Respir Crit Care Med 2003;167:A611.
40. Jordan A, Bhorade SM, et al. Increased IL 15 in bronchoalveolar fluid in acute lung
allograft rejection. AST 2003
41. Yu A, Bhorade SM, et al. Evaluation of risk factors for progression of BOS-OP to BOS Am J Respir Crit Care Med 2003;167:A246.
42. Bhorade SM et al. Liberalization of donor criteria does not compromise outcomes three
years after lung transplantation. Journal of Heart and Lung Transplantation 2003;
22:143. (oral presentation)
43. Bhorade SM et al. New combination of immunosuppressive therapy decreases acute
rejection in lung transplantation. Journal of Heart and Lung Transplantation 2003;
22:426.
44. Bhorade SM.et al. A comparison of three tacrolimus based immunosuppressive regimens
in lung transplantation. Am J Respir Crit Care Med 2002;165: B3
45. Jordan A, Bhorade SM. The natural history of bronchiolitis obliterans syndrome. Am J
Respir Crit Care Med 2002;165: B3
46. Kefer J, Bhorade SM, Villanueva J et al. Effect of recombinant human erythropoietin on
hemoblobin levels of anemic lung transplant recipients. Chest 2001
47. Jordan A, Bhorade SM, Lurain NS, et al. Emergence of ganciclovir resistant
cytomegalovirus in lung transplant recipients.American Society of Transplantation
2001(oral presentation)
48. Villanueva J, Bhorade SM, et al. Acute lung allograft rejection rates with three different
immunosuppressive regimens. American Journal of Respiratory and Critical Care
Medicine 163(5): A336;2001
49. Lanuza DM, Lefaiver CA, McCabe MA, Farcas GA, Bhorade SM, Garrity ER.
Functional status and medical complications during the first year post lung
transplantation. The Journal of Heart and Lung Transplantation 20(2): A163; 2001
50. Villanueva J, Khurshid A, Bhorade SM, Garrity ER. Sleep disturbances in lung
transplant recipients. (accepted for poster presentation APSS 2001
51. N. Lurain, D. Kohn, S. Bhorade et al. CMV Antiviral Drug Resistance in Solid Organ
Transplant Recipients.
52. Villanueva J, Bhorade S, McCabe MA, Husain A, Vigneswaran W,Garrity ER. The
utility of surveillance bronchoscopy in lung transplantation. American Journal of
Respiratory and Critical Care Medicine 161 (3):A719;2000.
53. Villanueva J, Bhorade S, McCabe MA, Husain A, Vigneswaran W,Garrity ER.
Dacluzimab, an anti-interleukin receptor antibody, may decrease the acute rejection in
lung transplant patients. The Journal of Heart and Lung Transplantation 19(1): A192;
2000(oral presentation)
54. Sandesara C, Bhorade S, Garrity E, Norwick L, McCabe, Husain A, Yeldandi V. Early
detection of CMV disease by the hybrid capture assay in lung transplantation. The
Journal of Heart and Lung Transplantation 19(1): A178; 2000(oral presentation)
55. Vigneswaran V, McCabe MA, Bhorade S, Bakhos M, Hinkamp TJ, Garrity ER. Cystic
fibrosis patients may require waiting time adjustment. The Journal of Heart and Lung
Transplantation 19(1): A79; 2000
56. Bhorade S, McCabe MA, Martin KL, Lonchyna V, Arcidi J, Hinkamp T, Garrity ER.
Succesful lung transplantation with the use of marginal donors. The Journal of Heart and
Lung Transplantation 18(1): A184; 1999(oral presentation)
57. Bhorade SM, Vence C, Garrity ER, Alex C, Simpson K, Husain AN, McCabe MA,
Yeldandi V. Treatment of infections in lung transplant patients with filgrastin (G-CSF)
does not induce rejection. Transplantation 67(7): A132,1999. (oral presentation)
58. Amstadt C, Bhorade SM, McCabe MA, Vigneswaran W, Garrity ER. The efficacy of
daclizumab, an anti-interleukin receptor antibody in the prevention of acute rejection in
lung transplantation. Transplantation 67(7): A388,1999.
59. Bhorade S, Christenson J, Pohlman A, Arnow P, Hall JB. Risk factors for colonization
by vancomycin resistant enterococcus during mechanical ventilation. American Journal
of Respiratory and Critical Care Medicine 157(3): A292, 1998.
60. Bhorade S,Christenson J, Pohlman A, Arnow P, Hall JB. Incidence and associated
outcome of colonization by vancomycin resistant eneterococcus during mechanical
ventilation. American Journal of Respiratory and Critical Care Medicine 157(3): A292,
1998.
61. Christenson J, Bhorade S, Pohlman A, Spencer K, Hall JB. The use of transnasal
transesophageal echocardiography for continous monitoring of right ventricular function
in patients receiving nitric oxide. American Journal of Respiratory and Critical Care
Medicine 155(4): A440, 1997.
62. Christenson J, Bhorade S, Pohlman A, Lavoie A, Kason T, O’Connor M, Hall JB.
Treatment of acute right ventricular failure with inhaled nitric oxide. American Journal of
Respiratory and Critical Care Medicine 155(4): A703, 1997
63. Christenson J, Bhorade S, Pohlman A, Lavoie A, Wylam M, O’Connor M, Hall JB.
Discontinuation of inhaled nitric oxide in acute hypoxemic respiratory failure: Adverse
effects on gas exhange and hemodynamics. American Journal of Respiratory and Critical
Care Medicine 155(4): A745, 1997.
64. Christenson J, Bhorade S, Pohlman A, Lavoie A, Wylam M, O’Connor M, Hall JB. The
effect of lung focality on response to inhaled nitric oxide in acute hypoxemic respiratory failure. American Journal of Respiratory and Critical Care Medicine 155(4): A91, 1997.
65. Renz C, Christenson J, Bhorade S, Pohlman A, Arnow P, Hall JB Assessment of
combination prophylaxis to prevent ventilator –associated pneumonia. American Journal
of Respiratory and Critical Care Medicine 155(4): A932, 1997.
66. Renz C, Christenson J, Bhorade S, Pohlman A, Ndukwu M, Arnow P, Hall JB
Prevention of ventilator associated pneumonia: Outcome and Resource Utilization.
American Journal of Respiratory and Critical Care Medicine 155(4): A19, 1997.
Book Chapters:
1. Floreth T, Bhorade SM. Special Considerations in Lung Transplantation in older
patients. In Aging and Lung Disease in Respiratory Medicine Book Series. (in press)
2. Wickii T. Vigneswaran, Sangeeta M. Bhorade. Post Operative Care Of The Lung
Transplant Patient. Surgical Intensive Care Medicine.(Second Edition). (Eds.) John
O’Donnell and Flavio Nacul. Springer, New York, 621-628, 2009.
3. McShane PJ, Bhorade SM. Maintenance immunosuppression in lung transplantation in
Lung. In Vigneswaran WT, Garrrity ER. Lung Transplantation. Lung Biology in Health
and Disease. Informa Healthcare UK April 2010
4.. McShane PJ, Bhorade SM. Augmentation of immunosuppression in lung transplantation
in Lung Transplantation. In Vigneswaran WT, Garrrity ER. Lung Transplantation. Lung
Biology in Health and Disease. Informa Healthcare UK April 2010
5. Lu BS, Garrity ER, Bhorade SM. Cyclosporine; Tacrolimus; Sirolimus; Azathioprine;
Mycophenolate Mofetil; Corticosteroids. Lung and Heart Lung Transplantation Marcel
Dekker series
6. Dickover B, Bhorade SM, Garrity ER. Lympholytic Agents (Polyclonal
Antilymphocyte Ab, Anti-CD3 Monoclonal antibodies, Anti-CD25 Monoclonal Ab)Lung
and Heart Lung Transplantation Marcel Dekker series
7. Bhorade SM, Villanueva J, Jordan A, Garrity ER. Modern concepts of
immunosuppression in lung transplantation. In Advances in Thoracic Surgery 2002
8. Garrity ER, Vigneswaran W, Bhorade SM. Pre-Transplant Evaluation of Donor/ Organ
Procurement. In Norman DJ, Suki WN ed. Primer on Transplantation, 2nd
Ed. New Jersey:
American Society of Transplant Physicians 2001.
9. Bhorade SM, Garrity ER. Organ Sharing and Allocation: Lung and Heart/ Lung. In
Norman DJ, Suki WN ed. Primer on Transplantation, 2nd
Ed. New Jersey: American Society
of Transplant Physicians 2001.
10. Bhorade SM, Vigneswaran W, Garrity ER. Lung Transplantation at Loyola University
Medical Center. In Cecka JM, Terasaki PJ ed. Clinical Transplants 1999, UCLA Tissue
Typing Laboratory.
11. Bhorade SM. Acute Hypoxemic Respiratory Failure. In: Hall JB, Schmidt GA, Wood
LDH ed. Principles of Critical Care Companion Handbook, 2nd
Ed. New York: McGraw-
hill, Inc. Health Professional Division, 1999.
12. Bhorade SM. Critical illness in pregnancy. In: Hall JB, Schmidt GA, Wood LDH ed.
Principles of Critical Care Companion Handbook, 2nd
Ed. New York: McGraw-hill, Inc.
Health Professional Division, 1999.
13. Bhorade SM. Monitoring the respiratory system. In: Hall JB, Schmidt GA, Wood
LDH ed. Principles of Critical Care Companion Handbook, 2nd
Ed. New York: McGraw-
hill, Inc. Health Professional Division, 1999.
14. Bhorade SM. Vasoactive medications. In: Hall JB, Schmidt GA, Wood LDH ed.
Principles of Critical Care Companion Handbook, 2nd
Ed. New York: McGraw-hill, Inc.
Health Professional Division, 1999.
Case Reports/Invited articles:
1. Bhorade SM. Lung Transplantation. (Book Review) Respiratory Care 2004; vol 49 ,
#10.
2. Bhorade S. and Schmidt G. Dealing with the risk of venothromboembolism (VTE) in
women using oral contraceptives. Journal of Respiratory Disease 19 (1): 8-11, 1998.
3. Hinkes E, Bhorade S, Wood LDH, Ndukwu IM. Young Adult with near-fatal
pneumonia caused by Adenovirus Serotype 7. Respiratory Care 44:524-527, 1999.
Other:
1. Walia R, Bhorade SM Practical Reviews.
2. Bhorade S, McShane P. Bronchiectasis. BMJ Point-of-Care 2009;
www.pointofcare.bmj.com. (Last accessed May, 2009)
3. Contributor to the ATS Best of the Web: Educational resources for lung transplantation
for health care professionals (10/2007- present)
4. Contributor to the ATS Basic Science Journal Club (12/00) Contributor to the ATS CME
web site (7/99,)
INVITED PRESENTATIONS AT NATIONAL/ INTERNATIONATIONAL
MEETINGS:
1. American Society of Transplantation. Co-moderator-Bronchiolitis Obliterans April
2002
2. American Thoracic Society. Lung Transplantation. Modern concepts of
immunosuppression Atlanta Georgia May 2002
3. American College of Chest Physicians. The management and diagnosis of acute and
chronic rejection. San Diego Nov 2002
4. International Congress on Lung Transplantation. Multicenter Rapamune trial in lung
transplantation. Paris France Sept 2002
5. International Congress on Lung Transplantation. Liberalization of donor criteria:
What limits to preserve good results? Paris France Sept 2002
6. American Thoracic Society. Bronchiolitis obliterans: diagnosis and therapeutic
options. Seattle WA May 2003
7. American College of Chest Physicians. What is the optimal immunosuppressive
regimen in lung transplantation? Orlando Fla Nov 2003
8. American Thoracic Society. New Immunosuppressives: Can they prolong survival
and improve quality of life? May 2004
9. American Thoracic Society. Infectious Complications after lung transplantation May
2004
10. International Congress on Lung Transplantation. Sirolimus in lung transplantation.
Paris France Sept 2004
11. International Congress on Lung Transplantation. Malignancy after lung
transplantation Paris France Sept 2004
12. American College of Chest Physicians Refractory rejection in the critically ill lung
transplant recipient. Seattle, WA Oct 2004
13. American Thoracic Society. San Diego, CA May 2006 Moderator Lung
Transplantation
14. World Transplant Conference Boston, MA July, 2006 Moderator Lung
Transplantation
15. International Society of Heart and Lung Transplantation. Utility of Cylex Immunoassay
in lung transplantation. San Francisco April 2007
16. American Thoracic Society. Effective control of Acute Rejection. San Francisco May
2007
17. American College of Chest Physicians. Lung transplantation for the hospitalized
patient: Is it ever appropriate? Con Chicago October 2007
18. American College of Chest Physicians. Diagnosis and treatment of fungal infections
in lung transplant recipients. Philadelphia PA October 2008
19. Catalan Transplant Society. Lung Allocation Score-It’s effect on pre- and post-
transplant mortality. Barcelona Spain February 2009
20. Catalan Transplant Society. Expanded donor criteria: Where is the limit? Barcelona
Spain February 2009
21. International Society of Heart and Lung Transplantation. New approaches to
monitoring the extent of immunosuppression Paris France April 2009
22. American Thoracic Society. Postgraduate course: Acute rejection: prevention,
detection and management Lung transplantation: State of the Art. San Diego CA May
2009
23. International Society of Heart and Lung Transplantation. Lymphocytic bronchiolitis.
Moderator Chicago IL April 2010
24. International Congress on Lung Transplantation. Recent results of the azathioprine
and rapamune trial Paris France Sept 2010
25. International Congress on Lung Transplantation. Quality of life after lung
transplantation Paris France Sept 2010
26. American College of Chest Physicians. What transplant drugs can only be given by
transplant centers? Vancouver Canada November 2010
27. American College of Chest Physicians. Acute immunosuppressive therapy-related
complications and considerations in the critically ill transplant recipient Vancouver
Canada November 2010
28. International Society of Heart and Lung Transplantation. Ganciclovir resistant CMV
disease. San Diego CA April 2011
29. International Society of Heart and Lung Transplantation. Bortezomib in Antibody
mediated rejection. San Diego CA April 2011
30. American Thoracic Society. Postgraduate course: Post transplant
immunosuppression. Denver CO May 2011
31. American Thoracic Society. Meet the Professor: Evolving concepts in the
pathogenesis and treatment of Bronchiolitis obliterans syndrome. Denver CO May 2011
INVITED GRAND ROUNDS:
1. Internal Medicine Grand Rounds, Loyola University of Chicago Medical Center. Lung
Transplantation-Who, When and Why? August, 1999.
2. Internal Medicine Grand Rounds, Loyola University of Chicago Medical Center.
Emerging concepts in interstitial pneumonitis July 2003
3. Internal Medicine Grand Rounds, Christ Hospital. Pulmonary infiltrates in a 15 year
old woman. Chicago, IL January 2005
4. Internal Medicine Grand Rounds, Our Lady of the Resurrection Hospital. Community
Acquired Pneumonia Chicago, IL February 2005
5. Internal Medicine Grand Rounds, Chicago Medical School. Surgical Treatments for
COPD. North Chicago, IL August 2006
6. Internal Medicine Grand Rounds, St Joseph Hospital. Lung Transplantation 2008: An
Update Chicago February 2008
7. Internal Medicine Grand Rounds, University of Texas, Galveston. Lung
Transplantation: The good, the bad and the better…. July 2008
8. Pulmonary Grand Rounds. University of Miami, Miami Florida. Lung
Transplantation: A new era. February 2009
9. Pulmonary Grand Rounds. Rush University. Lung Transplantation: An update.
December 2009
10. Internal Medicine Grand Rounds, Chicago Medical School. Lung Transplantation for
COPD. North Chicago, IL September 2010
11. Transplant Medicine Grand Rounds. Methodist Hospital. Baylor College of
Medicine. The Changing Face of lung transplantation. November 2010
12. Pulmonary Grand Rounds, Loyola University of Chicago Medical Center. The
Changin Face of lung transplantation. March 2011
INVITED LECTURES (LOCAL)
1. National Sarcoidosis Association Annual Awareness Conference. Sarcoidosis and
Lung Transplantation. June, 1999.
2. Cystic Fibrosis Awareness Day. Cystic Fibrosis and Lung Transplantation.
September, 1999.
3. Chicago Medical Society Midwest Clinical Conference 2000: Selection criteria for lung
transplant recipients. February 2000.
4. State of the Art immunosuppression in Transplantation; Peoria IL The use of sirolimus
in solid organ transplantation. February 2001
5. Annual Far Eastern Internal Medicine Meeting; Chicago, IL: Asthma September 2001
6. End stage lung disease symposium; Loyola University Medical Center (course
director): Idiopathic pulmonary fibrosis. November 2001
7. Alpha 1 Antitrypsin Society. Alpha 1 antitrypsin and lung transplantation Chicago
June 2002
8. End stage lung disease symposium. Loyola University Medical Center (co-course
director): Pulmonary hypertension September 2002
9. Alpha 1 Antitrypsin Society. Alpha 1 antitrypsin and lung transplantation Chicago
June 2003
10. Cleveland Clinic Pulmonary Conference. Update in lung transplantation. Cleveland,
OH February 2006
11. University of Illinois Pulmonary Conference. Lung Transplantation. Chicago, IL
October 2006
12. Chicago Medical School. Advances in COPD Symposium. Improving outcome in
COPD Chicago, IL November 2006
13. Advanced Lung Disease Symposium. Course Moderator. Medical Complications
after lung transplantation. (50 local pulmonologists ¾ day conference) Chicago October
2008
14. University of Chicago Undergraduate Course. Lung Transplantation January 2011
GRANTS:
7/06-7/11 5R01HL081619 NIH/ NHLBI
PI- J Christie MD
Co-investigator- S. Bhorade, MD
Genetics of primary graft dysfunction
7/09-7/11 1R21AI083527-01 NIH/NIAID
PI- Steven White, MD,
Co-investigator- S. Bhorade, MD
Role of epithelial HLA-G in lung transplantation
2/02-12/09 Fujisawa Award- $1,500,000
Multicenter lung transplant study: Comparison of a de novo tacrolimus/sirolimus/prednisone
regimen versus a tacrolimus/azathioprine/prednisone immunosuppressive regimen in lung
transplantation.- P.I.- S. M. Bhorade,MD
11/06-11/07 U Chicago DOM Lung Transplant Research Award Correlation of Lung
Biopsy, BAL, and High Resolution CT Scan in Lung Transplantation. Can we Help
Diagnose Acute Rejection and Better Predict Bronchiolitis Obliterans? Garrity ER (PI),
Bhorade (Co-investigator)
11/06-11/07 U Chicago DOM Lung Transplant Research Award Bhorade (PI)
Comparison of TLR signaling and Treg infiltrating profiles between stable and infected lung
allografts in human lung transplant recipients
2/02-12/06 RO1 HLO72871-01 NIH Award Matalon (PI)
Modulation of innate immunity in lung transplantation by tacrolimus and sirolimus.
Role: Consultant
4/01-4/04 ALA grant- $35,000 x 3years
Pathogenesis of cytomegalovirus in lung transplantation- P.I- Nell Lurain, PhD, Co-
investigator- S.M. Bhorade, MD
7/00-6/05 RO1 NR05284-03 NIH Award - $1,700,000
Predictors of Quality of Life: Lung Transplant Patients-P.I.- Dorothy Lanuza,RN,PhD, Co-
investigator- S. M. Bhorade, MD
1/00-6/01 Fujisawa Award- unrestricted grant- $75,000
Evaluation of induction therapy with a humanized monoclonal antibody in addition to triple
drug immunosuppressive therapy in lung transplantation-a single center pilot study- P.I.- S.
M. Bhorade,MD, Co-investigator- Edward Garrity, Jr., MD .
1/00-6/00 RFC grant (Bane)- $20,000
Factors predicting quality of life in lung transplant patients: A longitudinal study- P.I. SM
Bhorade, MD, co investigator- Dorothy Lanuza
4/01-4/03 Wyeth-Ayerst Award- unrestricted grant-$60,000.
Conversion to sirolimus in the treatment of Bronchiolitis Obliterans Syndrome in lung
transplantation- P.I.- S. M. Bhorade,MD
CONTRACTS:
A Study to Evaluate Viral Quantity and Shedding as a Function of Time in Adult Lung
Transplant Patients with RSV Infection.P.I. SM Bhorade, MD
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the
Safety and Antiviral Activity of Aerosolized ALN-RSV01 Plus Standard of Carein Lung
Transplant Patients Infected with Respiratory Syncytial Virus (RSV) P.I. SM Bhorade, MD
A Multi-center, Randomized, Controlled Study to Demonstrate the Efficacy and Safety of
Cyclosporine Inhalation Solution (CIS) in Improving Bronchiolitis Obliterans Syndrome-
Free Survival Following Lung Transplantation P.I. SM Bhorade, MD
A Phase III, Randomized, Double-blind Comparison of Oral Valganciclovir and Placebo for
Prevention of CMV Infection After Lung Transplantation P.I.- Edward Garrity, Jr., MD, CO
P.I.- SM Bhorade, MD
A Long-Term Study of Ambrisentan in Pulmonary Arterial Hypertension Subjects Having
Completed AMB-320 or AMB-321. P.I. SM Bhorade, MD-closed
A Phase II, randomized, Double-Blind, Placebo-Controlled, Study of the Safety and Clinical
Effects of (Gleevec Imatinib Mesylate) Administered Orally in Patients with Idiopathic
Pulmonary Fibrosis. P.I.- SM Bhorade, MD-closed
Randomized, double-blind, placebo-controlled, phase III study of the safety and efficacy of
subcutaneous recombinant interferon gamma-1b in patients with idiopathic pulmonary
fibrosis. P.I.- S. M. Bhorade, MD-closed
Three year randomized multi-center double blind parallel group study of the efficacy and
safety of SDZ RAD, azathioprine as adjunctive immunosuppressive therapy to inhibit the
decline of pulmonary function in lung or heart/lung transplant recipients at risk for
developing bronchiolitis obliterans syndrome- P.I.- Edward Garrity, Jr., MD, Co-
investigator- S.M. Bhorade, MD direct cost-$37,000.-closed
One year randomized multi-center open labelled parallel group study of the efficacy and
safety of RAD001 tablets versus antithymocyte globulin and azathioprine in lung or
heart/lung transplant with bronchiolitis obliterans syndrome- P.I-Edward Garrity,Jr., MD,
Co-investigator- S.M. Bhorade, MD direct cost-$7,000-closed.